FDA approves lower dose of cabazitaxel in treatment of mCRPC

Posted on September 15, 2017 by Sitemaster

Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a comment »

  • Donate

  • PCaI’s ASVSG

    If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.

  • CureTalks on PCa

    Our most recent CureTalk on Prostate Cancer (on February 21 this year)  features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.

    For access to the full list of CureTalks on Prostate Cancer, please click here.

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives